# Pemvidutide > Altimmune’s once-weekly balanced glucagon / GLP-1 dual agonist — developed liver-first, with a Phase 3 MASH trial (PERFORMA) that began in 2026. - Also known as: ALT-801 - Class: Metabolic - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/pemvidutide ## Overview Pemvidutide is an investigational once-weekly peptide that activates the glucagon and GLP-1 receptors in roughly equal measure — a more glucagon-weighted balance than survodutide or mazdutide. Altimmune is developing it primarily for MASH rather than obesity. The Phase 2b IMPACT trial reported MASH resolution without worsening of fibrosis in 52–59% of treated participants at 24 weeks versus 19% on placebo, an effect sustained to 48 weeks, and the Phase 3 PERFORMA trial began in August 2026. It holds FDA Fast Track and Breakthrough Therapy designations for MASH and is not approved. Glucagon/GLP-1 dual agonists differ in how much glucagon activity they carry. Survodutide and mazdutide lean toward GLP-1; pemvidutide is closer to an even split. More glucagon means more direct action on the liver — the organ richest in glucagon receptors — which is the rationale for developing it as a liver drug first. It also takes a distinct approach to tolerability. Instead of a conventional fatty-acid chain, the peptide carries a glycolipid surfactant-like moiety (Altimmune’s EuPort domain) intended to slow entry into the bloodstream and flatten the concentration peak, with the aim of allowing dosing without a long titration. In the Phase 2 MOMENTUM obesity trial, the 2.4 mg dose produced 15.6% mean weight reduction at 48 weeks. In the Phase 2b IMPACT trial in biopsy-confirmed MASH, 59.1% and 52.1% of participants on 1.2 mg and 1.8 mg achieved MASH resolution without worsening of fibrosis at 24 weeks versus 19.1% on placebo; fibrosis improvement did not reach statistical significance at that early timepoint. The 48-week data reported in December 2025 showed the effect was sustained, with adverse-event discontinuations below 2%. The global Phase 3 PERFORMA trial began enrolling in August 2026, testing 1.8 mg and 2.4 mg on biopsy endpoints, with a 52-week readout expected in 2029. Mid-stage trials in alcohol use disorder and alcohol-associated liver disease are also running. ## Mechanism Balanced (approximately 1:1) agonism at the glucagon and GLP-1 receptors. The glucagon arm drives hepatic fat oxidation and energy expenditure; the GLP-1 arm supplies appetite and glycemic effects. A proprietary glycolipid side chain slows absorption to blunt peak concentrations. ## Research areas Studied in: MASH, Obesity, Alcohol use disorder, Alcohol-associated liver disease. Guides on this site: - [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss. ## Key research - Balanced glucagon / GLP-1 agonism — roughly 1:1, more glucagon-weighted than survodutide or mazdutide, for direct hepatic effect. - IMPACT (Phase 2b MASH) — MASH resolution without worsening fibrosis in 59.1% (1.2 mg) and 52.1% (1.8 mg) versus 19.1% placebo at 24 weeks; sustained at 48 weeks. - Fibrosis — improvement did not reach statistical significance at 24 weeks; the Phase 3 trial tests it on biopsy at 52 weeks. - MOMENTUM (Phase 2 obesity) — 15.6% mean weight reduction at 48 weeks on 2.4 mg. - Status — Phase 3 PERFORMA (MASH) began August 2026, readout expected 2029; FDA Fast Track and Breakthrough Therapy designations; investigational. ## FAQs ### What is pemvidutide? Pemvidutide (ALT-801) is an investigational once-weekly glucagon / GLP-1 dual receptor agonist from Altimmune, developed mainly for MASH (fatty liver disease with inflammation) and also studied in obesity and alcohol-related conditions. ### How is pemvidutide different from survodutide and mazdutide? All three activate the glucagon and GLP-1 receptors, but pemvidutide is closer to a 1:1 balance, giving it relatively more glucagon activity. It also uses a glycolipid side chain to slow absorption. Its lead indication is MASH rather than obesity. ### What did the MASH trial show? In the Phase 2b IMPACT trial, 52–59% of participants on pemvidutide achieved MASH resolution without worsening of fibrosis at 24 weeks versus 19% on placebo, sustained through 48 weeks. Improvement in fibrosis itself was not statistically significant at 24 weeks. ### Does pemvidutide cause weight loss? Yes — the Phase 2 MOMENTUM trial reported 15.6% mean weight reduction at 48 weeks on the 2.4 mg dose. Obesity is not currently its lead development program. ### Is pemvidutide approved? No. It is investigational; the Phase 3 PERFORMA trial in MASH began in August 2026 with a readout expected in 2029. This page is a research reference, not medical advice. ## Latest research Recent trials and publications mentioning Pemvidutide, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH](https://clinicaltrials.gov/study/NCT07795164) — RECRUITING · PHASE3 · NCT07795164 - [RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)](https://clinicaltrials.gov/study/NCT07009860) — ACTIVE_NOT_RECRUITING · PHASE2 · NCT07009860 - [RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight](https://clinicaltrials.gov/study/NCT06987513) — COMPLETED · PHASE2 · NCT06987513 - [IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)](https://clinicaltrials.gov/study/NCT05989711) — COMPLETED · PHASE2 · NCT05989711 - [Pemvidutide (ALT-801) DDI Study in Healthy Volunteers](https://clinicaltrials.gov/study/NCT04972396) — COMPLETED · PHASE1 · NCT04972396 - [ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability](https://clinicaltrials.gov/study/NCT04561245) — COMPLETED · PHASE1 · NCT04561245 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/pemvidutide Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.